selective CDK2/4/6 inhibitor

oral agent in Ph. I/IIa for HR+ HER2- cancers

screen for CDK1/2 sel., SBDD + Free-Wilson

Journal of Medicinal Chemistry

Pfizer, San Diego, US

5. The Pfizer CDK2/4/6 inhibitor PF-60873600 is orally bioavailable with Ki values of 0.09 nM, 1.3 nM, and 0.16 nM for CDK2, CDK4, and CDK6, respectively, with lower activities…

 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.